- Company
recently announced significant findings of cardiovascular performance
improvements with TurboCBD
- Lexaria
plans additional human clinical trials of CBD
- Company
is now moving forward with clinical studies on oral forms of nicotine
delivery following a large investment agreement
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a food
bioscience company that developed and commercialized cost-effective drug
delivery platform DehydraTECH. This technology enhances the performance of
beneficial compounds in ingestible products. Currently, Lexaria has patents
pending worldwide for use of the technology in a range of bioactive molecules,
including cannabinoids, nicotine, NSAID pain relievers and more. Leveraging
this platform, the taste, smell, speed of action, bioabsorption and
bioavailability of oral ingestion is improved without the harmful practices of
lighting up or the unhealthy additions of sugars and sweeteners. The company
licenses DehydraTECH to other companies around the world to enhance already
established, quality product lines.
TurboCBD is Lexaria’s proprietary DehydraTECH-powered,
CBD-fortified hemp-oil capsule. The capsules are formulated with full-spectrum
hemp oil, ginseng and ginkgo for enhanced focus and memory. They are
marketed as a mental and physical boost aimed at helping to remove brain fog,
fatigue and stress. TurboCBD is molecularly engineered for quick and high
absorption rates into the circulatory system.
In a recent press release (http://ibn.fm/OwOtT), Lexaria announced that the results
from a healthy-human clinical trial provided evidence that a single 90mg dose
of TurboCBD resulted in lower blood pressure, higher blood flow to the brain,
faster delivery onset of CBD into the bloodstream and larger quantities of CBD
within the blood as compared to an equal dose of generic CBD. Due to the
positive results of this study, the company plans to conduct additional human
clinical trials over the course of the next year using DehydraTECH in CBD.
A comprehensive series of clinical studies will also
continue on oral forms of nicotine delivery. Lexaria Nicotine LLC, a wholly
owned subsidiary, has entered into an investment agreement that will provide an
initial $1 million, with additional funding of up to $12 million, toward the
research and development of nicotine consumer products enhanced by DehydraTECH.
DehydraTECH is an enabling drug-delivery platform with
relevance across multiple industries. The company utilizes subsidiaries that
reach across industry lines, making it accessible to the medical and
recreational cannabis industries and pharmaceutical sectors. The company has
formed a partnership with one of the world’s largest tobacco companies (http://ibn.fm/v91xQ). Currently,
Lexaria owns 10 patents with over 50 patents pending worldwide for this
revolutionary technology. Lexaria is ahead of the game, doing business on its
terms and attracting the attention of Fortune 500-type corporations.
For more information, visit the company’s website at www.LexariaBioscience.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
